NCT04652921

Creatine-Guanidinoacetic Acid Supplementation for Sarcopenia (CREGAAS)

The Effects of 6-month Supplementation With Creatine and Guanidinoacetic Acid on Biomarkers of Sarcopenia in Elderly

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: University of Novi Sad, Faculty of Sport and Physical Education · Academic / Other
• Sex: All
• Age: 65 Years – 90 Years
• Healthy volunteers: Accepted

Summary

Sarcopenia-driven brain and muscle creatine deficit could be seen as a distinctive pathological facet of this condition, and this might be approached with targeted therapies in aim to restore creatine homeostasis in target tissues. Among potential therapeutic candidates, guanidinoacetate (GAA) appears recently as a direct precursor of creatine that may favorably upregulate muscle and brain creatine concentration. Interestingly, GAA-creatine mixture was found to be superior than creatine itself to effectively improves bioenergetics in the human brain and muscle in healthy humans, perhaps due to the unique transportability features of this combination. Here, we plan to evaluate does creatine-GAA supplementation affects various biomarkers of sarcopenia in elderly.

Conditions

• Sarcopenia

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Creatine-guanidinoacetic acid	A dietary supplement provided as powder dissolved in a glass of water
OTHER	Inulin	A dietary supplement provided as powder dissolved in a glass of water

Timeline

• Start date: 2020-09-15
• Primary completion: 2021-12-15
• Completion: 2021-12-31
• First posted: 2020-12-03
• Last updated: 2022-11-01

Locations

1 site across 1 country: Serbia